Brief: Oncosec Announces Initiation Of Phase 2 Study To Evaluate Combination Of Tavo Plus Opdivo As Neoadjuvant Therapy For Melanoma
27/08/2020 13:39
Aug 27 (Reuters) - OncoSec Medical Inc ONCS.O :
* ONCOSEC ANNOUNCES INITIATION OF A PHASE 2 STUDY AT THE
MOFFITT
CANCER CENTER TO EVALUATE THE COMBINATION OF TAVO PLUS OPDIVO®
AS NEOADJUVANT THERAPY FOR MELANOMA
* ONCOSEC MEDICAL INC - PHASE 2 STUDY WILL HIGHLIGHT
ADVANTAGES OF
BRINGING TAVO INTO AN EARLIER DISEASE SETTING
Source text for Eikon: ID:nPn7Llbf3a
Further company coverage: ONCS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on OncoSec Medical Incorporated
See all newsBrief: OncoSec Medical Inc On June 15 Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
U.S. STOCKS ON THE MOVE-Domino's, Aldeyra, MicroVision
Brief: OncoSec Medical Files Voluntary Petition For Relief Under Provisions Of Chapter 7 Of Title 11 Of United States Code
Brief: OncoSec Medical Terminates George Chi For Cause As Employee, CFO
Brief: Oncosec Medical Receives Non Compliance Notice From Nasdaq